[1] KHACHATURIAN Z S. Diagnosis of Alzheimer's

disease[J]. Arch Neurol，1985，42（11）：1097-1105.

[2] VILLEMAGNE V L，DORE V，BURNHAM S C，

et al. Imaging tau and amyloid-beta proteinopathies

in Alzheimer disease and other conditions[J]. Nat

Rev Neurol，2018，14（4）：225-236.

[3] JACK C R，JR. ，BENNETT D A，BLENNOW

K，et al. NIA-AA Research Framework：Toward

a biological definition of Alzheimer's disease[J].

Alzheimers Dement，2018，14（4）：535-562.

[4] Alzheimer's Association. 2017 Alzheimer's disease

facts and figures[J]. Alzheimer's & Dementia，2017，

13（4）：325-373.

[5] MASTERS C L，CAPPAI R，BARNHAM K J，et

al. Molecular mechanisms for Alzheimer's disease：

implications for neuroimaging and therapeutics[J]. J

Neurochem，2006，97（6）：1700-1725.

[6] PETERSEN R C，SMITH G E，WARING S C，et al.

Mild cognitive impairment：clinical characterization

and outcome[J]. Arch Neurol，1999，56（3）：303-

308.

[7] HARDY J，SELKOE D J. The amyloid hypothesis of

Alzheimer's disease：progress and problems on the

road to therapeutics[J]. Science，2002，297（5580）：

353-356.

[8] KLUNK W E，ENGLER H，NORDBERG A，et al.

Imaging brain amyloid in Alzheimer's disease with

Pittsburgh Compound-B[J]. Ann Neurol，2004，55

（3）：306-319.

[9] JOHNSON K A，MINOSHIMA S，BOHNEN

N I，et al. Appropriate use criteria for amyloid

PET：a report of the Amyloid Imaging Task Force，

the Society of Nuclear Medicine and Molecular

Imaging，and the Alzheimer's Association[J/OL].

Alzheimers Dement，2013，9（1）：e1-e16. https：//

doi.org/10.1016/j.jalz.2013.01.002.

[10] IKONOMOVIC M D，KLUNK W E，

ABRAHAMSON E E，et al. Post-mortem correlates

of in vivo PiB-PET amyloid imaging in a typical

case of Alzheimer's disease[J/OL]. Brain，2008，131

（Pt 6）：1630-1645. https：//doi.org/10.1093/brain/

awn016.

[11] MUCKE L，SELKOE D J. Neurotoxicity of amyloid

beta-protein：synaptic and network dysfunction[J].

Cold Spring Harb Perspect Med，2012，2（7）：1-17.

[12] ROWE C C，ELLIS K A，RIMAJOVA M，et

al. Amyloid imaging results from the Australian

Imaging，Biomarkers and Lifestyle（AIBL）study of

aging[J]. Neurobiol Aging，2010，31（8）：1275-1283.

[13] VILLEMAGNE V L，PIKE K E，DARBY D，et al.

Abeta deposits in older non-demented individuals

with cognitive decline are indicative of preclinical

Alzheimer's disease[J]. Neuropsychologia，2008，46

（6）：1688-1697.

[14] FORMAN M S，MUFSON E J，LEURGANS S，et

al. Cortical biochemistry in MCI and Alzheimer

disease：lack of correlation with clinical diagnosis[J].

Neurology，2007，68（10）：757-763.

[15] MORRIS J C，PRICE J L. Pathologic correlates of

nondemented aging，mild cognitive impairment，and

early-stage Alzheimer's disease[J]. J Mol Neurosci，

2001，17（2）：101-118.

[16] PRICE J L，MORRIS J C. Tangles and plaques in

nondemented aging and "preclinical" Alzheimer's

disease[J]. Ann Neurol，1999，45（3）：358-368.

[17] DUBOIS B，FELDMAN H H，JACOVA C，et

al. Advancing research diagnostic criteria for

Alzheimer's disease：the IWG-2 criteria[J]. Lancet

Neurol，2014，13（6）：614-629.

[18] LOCKHART S N，BAKER S L，OKAMURA N，et

al. Dynamic PET Measures of Tau Accumulation in

Cognitively Normal Older Adults and Alzheimer’s

Disease Patients Measured Using[18F] THK-5351[J/

OL]. PLoS One，2016，11（6）：e0158460. https：//

doi.org/10.1371/journal.pone.0158460.